- Continue Shopping
- Your Cart is Empty
Hexoskin in South San Francisco for the 3rd Annual Clinical Trial Innovation Summit 2026 at Genentech
Hexoskin is proud to sponsor the 3rd Annual Clinical Trial Innovation Summit this October 13th hosted at Genentech in South San Francisco.
Over the past 10 years, the research community has invested heavily in AI, digital biomarkers, digital twins, decentralized trials, tokenization, and digital health technologies. We've learned when these technologies are useful and valuable, and when they're not. Now it's time to make them work at scale, across sites, populations, in ways that patients and sponsors both feel.
The gap between a successful pilot and routine, patient-centered practice is called the “valley of adoption” and is the focus of this year's summit. More than 25 speakers and over 200 senior leaders in clinical research, operations, and trial design will look at where innovation is delivering measurable value, where implementation still stalls, and how good approaches can be scaled responsibly.
What crossing the valley looks like from our side
At Hexoskin, we’ve learned that adoption depends less on what a technology can measure and more on how we operationalize it in a successful trial. Here’s what we bring to sponsors working to close that gap:
-
A dedicated team that supports your study from protocol design to biostatistical analysis. More than sensors and a software platform for managing data collection across sites and cohorts of patients, our team support you through all the steps of a trial, include site training, tech support, and logistics.
-
Only FDA-cleared wearable for both cardiac and respiratory markers. The Hexoskin Smart Shirt records 3-lead ECG, dual-channel respiratory inductance plethysmography (RIP), and 3-axis accelerometry, all from one comfortable garment. Respiratory patterns are rarely captured continuously outside the lab, and Hexoskin has pioneered their use for many disease categories.
- 112 digital biomarkers from a single device. These range from heart rate variability and breathing patterns to gait, sleep, and physical activity. Sponsors can choose the endpoints that matter for their program without adding devices, or burden, for participants.
- Endpoints and early signals across therapeutic areas. Hexoskin data supports research in neurology, rare diseases, and respiratory disease, among other areas. In rare disease especially, a small population means every data point and patient reported outcome is especially valuable.
- A growing body of evidence. Hexoskin has been used in more than 350 scientific publications. You can browse the literature by field in our online paper database.
Contact our team for more information.
Medtech Veteran and Serial Entrepreneur Jean-Pierre Desmarais joins Hexoskin's Board of Directors
Hexoskin announces today the nomination of Jean-Pierre Desmarais as an independent director on Hexoskin's Board of Directors.
Jean-Pierre Desmarais brings more than four decades in the medical device industry, spanning R&D, clinical research, regulatory affairs, and global commercialization. His background includes serving as Chief Scientific Officer at CryoCath Technologies (acquired by Medtronic) in the field of cardiac electrophysiology, President of Piramal Healthcare Bio-Orthopedics (acquired by Smith+Nephew), and CEO of Innovitech, an innovation advisory firm working across medical technology and aerospace. He currently serves as CEO of Leaflet solution who develops devices that facilitate transcatheter cardiac valve implantation.
Across his career, Jean-Pierre has guided medical technologies from early-stage development through regulatory approval, including FDA, EU CE, and other international pathways, and into global commercial and reimbursement markets. That perspective brings real value to the Hexoskin team as it accomplishes its mission: delivering medical wearables as a trusted source of digital biomarkers in cardiology, respiratory, neurology, and rare disease clinical trials.
About Hexoskin
Hexoskin is a Montreal-based medtech company that develops the Hexoskin Medical Shirt, a unique FDA-cleared wearable that continuously captures 3-lead ECG, dual-channel respiratory inductance plethysmography, and 3-axis accelerometry. Hexoskin's data is used as digital biomarkers and clinical endpoints in pharmaceutical trials spanning cardiology, respiratory, neurology, and rare disease programs, giving research teams continuous, clinical-grade physiological data outside traditional clinical settings. Behind this work sits a large proprietary cardiorespiratory database spanning over 300 studies — a unique foundation that Hexoskin is building on through AI research focused on respiratory and neurological diseases.
Hexoskin in Basel for the Digital Biomarkers in Clinical Trials & Clinical Trial Innovation Summits June 23-24
Hexoskin is proud to sponsor this week the 9th Digital Biomarkers in Clinical Trials Summit and the 6th Clinical Trial Innovation Summit, hosted in partnership with Roche in Basel, Switzerland.
View full article →Hexoskin in San Diego for BIO 2026
Hexoskin will be in San Diego this June 22-24 for the BIO 2026 International Convention, the world's largest and most comprehensive event for the global biotechnology and life sciences industry. Hosted by the Biotechnology Innovation Organization, the gathering brings together over 20,000 leaders from startups, Pharma companies, academia, and government agencies
View full article →Hexoskin at the Phoenix Global Forum 2026
Hexoskin's CEO Pierre-Alexandre Fournier will speak at the Phoenix Global Forum 2026 this May 13th at the Phoenix Convention Center.
He will be joined on stage by Jay Maningo-Salinas, Vice Chair, Research Administration at Mayo Clinic, and Brad Sorenson, founder and CEO at Providence Therapeutics to talk about healthcare innovation in biotech, medtech, and AI, and how the latest breakthrough offers an opportunity to fill health equity gaps in historically underrepresented populations.
The panel will be moderated by Jessica Boehm, reporter at Axios.
View full article →Hexoskin @ LSI USA 2026
Fresh off FDA clearance, Hexoskin will be in Dana Point this March at the annual LSI USA conference where we’ll be discussing our expansion plans with partners and investors.
We'll also present new developments about our AI models for clinical trials and remote diagnostics, and our digital biomarker pipeline in cardiology, respiratory diseases, nervous system disorders, and rare diseases.
Contact us if you're attending: contact@hexoskin.com
Hexoskin @ 2026 JP Morgan Conference
Hexoskin will be in San Francisco again this year during the 44th Annual J.P. Morgan Healthcare Conference, the largest life sciences investment event in the world.
We'll take the opportunity to meet with our clients and partners who use the Hexoskin software platform and wearables for clinical research, digital biomarker discovery, and medical AI development.
We'll also present new insights about the Hexoskin OneView platform for clinical research and our digital biomarker pipeline in cardiology, respiratory diseases, nervous system disorders, and rare diseases.
Contact us to book a meeting: contact@hexoskin.com
Hexoskin to Present at the HITLAB Innovation Summit 2025
Hexoskin's CEO Pierre-Alexandre Fournier is going to present our latest work in AI and digital biomarker development for clinical trials at the HITLAB Innovators Summit 2025 this December 2-4 in New York City.
Hexoskin Medical System Receives FDA 510(k) Clearance for Long-Term ECG and Respiratory Monitoring
The Hexoskin Medical System (HMS) is now an FDA-cleared, medical-grade smart shirt for continuous, long-term ECG, respiratory, and activity monitoring. It’s a premier remote monitoring solution for cardiopulmonary chronic conditions (COPD, Afib) and complements the validated AI-based digital biomarker platform for clinical trials in cardiovascular, respiratory, and rare diseases.
View full article →Hexoskin @ HLTH 2025
Hexoskin will be presenting its latest products and clinical advancements at HLTH USA 2025 next week in Las Vegas.
We'll take the opportunity to meet with our clients and partners who use the Hexoskin software platform and wearables to advance our knowledge of human physiology.
We'll also present our new Hexoskin OneView platform for research and our digital biomarker pipeline in cardiology, respiratory diseases, nervous system disorders, and rare diseases.
Contact us to book a meeting: contact@hexoskin.com
